Based in Nouvelle-Aquitaine, XIMED is a MedTech startup developing innovative solutions for the early diagnosis of breast cancer. Its technological expertise, recently highlighted by specialized media and its double selection at JFR 2025, confirms its position at the forefront of medical imaging innovation.
In recent weeks, XIMED has gained increased visibility within the MedTech ecosystem, thanks to specialized media coverage and recognition at leading industry events.
A committed player in the deeptech and MedTech sectors, XIMED develops and deploys a range of innovative products, such as BrightX and PhoeniX, designed to integrate seamlessly into the diagnostic and care pathway for breast cancer.
Growing recognition in the MedTech and radiology ecosystem
Leading media outlets, such as Tech Imago and Docteur Imago, have recently highlighted the relevance and impact of XIMED’s innovations in medical imaging, particularly in breast cancer diagnosis.
This targeted recognition is complemented by other media mentions:
As well as XIMED’s selection at the Inpho Venture Summit, demonstrating the growing interest in the company’s technological advancements.
This momentum was further reinforced by a double selection at the Journées Francophones de Radiologie (JFR 2025), a major event for medical imaging professionals.
XIMED participated both as an exhibitor at the Innovation Village and as a finalist for the Start-up Innovation Award, alongside the most promising companies in the field.
This recognition was granted by a jury of experts including representatives from the French Society of Radiology (SFR), Medicen Paris Region, the SNITEM, and the French Healthcare Association.
Visibility that strengthens a lasting presence in the ecosystem
These distinctions and media mentions represent a strong sign of institutional recognition and reinforce XIMED’s position as a leading innovator in medical technology, as well as a key player in the entrepreneurial ecosystem of Nouvelle-Aquitaine and the MedTech sector.
They also highlight the impact and relevance of XIMED’s solutions, which contribute to early breast cancer diagnosis while reducing the need for invasive procedures, often stressful for patients, time-consuming for healthcare professionals, and costly for healthcare systems.
Through its innovations, XIMED helps improve patient care pathways and optimize therapeutic strategy.
Beyond immediate recognition, this institutional and media visibility positions XIMED within a sustainable trajectory of excellence.
It demonstrates the company’s ability to bring together partners, hospitals, and industry stakeholders around a regional innovation in X-ray imaging, now recognized at a national level, and to assert its role in building a competitive, innovative, and health-focused medical and economic ecosystem.
